24/7 Market News Snapshot 06 October, 2025 – Spruce Biosciences, Inc. Common Stock (NASDAQ:SPRB)

October 6, 2025

DENVER, Colo., 06 October, 2025 (www.247marketnews.com) – (Nasdaq:SPRB) are discussed in this article.
Spruce Biosciences, Inc. (Nasdaq:SPRB) is experiencing significant momentum following the announcement that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its enzyme replacement therapy, tralesinidase alfa (TA-ERT), aimed at treating Sanfilippo Syndrome Type B (MPS IIIB). This breakthrough is crucial for advancing treatment options for this ultra-rare genetic disorder that severely impacts children’s neurological functions.

The recent surge in the company’s stock price reflects heightened investor interest, with shares climbing 48.58% to $13.105 in pre-market trading, up from a previous close of $8.820. The trading session has been robust, with a volume of 1.80 million shares, indicating strong market support and optimism about the company’s future prospects. Technical analysts note the importance of this upward movement, highlighting the potential for further gains as the stock breaks through key resistance levels.

Dr. Javier Szwarcberg, CEO of Spruce Biosciences, expressed his enthusiasm for the FDA’s acknowledgment of TA-ERT, emphasizing its rapid and significant effectiveness in clinical studies that have shown the therapy can restore critical neurological functions by normalizing pathogenic changes associated with neurodegeneration. This therapy seeks to replace the deficient N-Acetyl-Alpha-Glycosaminidase enzyme, which is vital for processing heparan sulfate within lysosomes. Without adequate treatment, children with MPS IIIB experience progressive neurological decline with few available therapeutic options.

The FDA’s BTD facilitates a faster development and regulatory review process, enabling Spruce to engage in collaborative efforts to refine TA-ERT’s path to market. The company anticipates submitting a Biologics License Application for TA-ERT in early 2026, bolstering its commitment to addressing significant unmet medical needs within the realm of neurological disorders.

Related news for (SPRB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.